• Product NameLY2090314
• Brief DescriptionInhibitors
• Purification99.81%
• Biological ActivityLY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. Phase 2.
• Target NameGSK-3 inhibitor
• CAS No. 603288-22-8
• Calculated MW 512.53
• Formulation C28H25FN6O3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Other
  SMILES:FC1=CC2=C3N(CCN(C2)C(=O)N2CCCCC2)C=C(C3=C1)C1=C(C(=O)NC1=O)C1=CN=C2C=CC=CN12
  Pathways:PI3K/Akt/mTOR signaling; Stem Cells
  Receptor:GSK-3α; GSK-3β
  Boling pt:
  Melting pt:
  Solubility:Ethanol: 2 mg/mL warmed (3.9 mM); DMSO: 100 mg/mL (195.11 mM)
  Appearance:Orange Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Brail LH, et al. J Clin Oncol, 2011, 29, abstr 3030.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting